본 연구는 자일로올리고당의 과학적이고 체계적인 표준 화된 시험법을 마련하여 다양한 제형의 제품에 적용하고 자 하였다. 최적화된 시험법을 마련하기 위해 초음파 처 리 시간, 산 가수분해 시간 및 농도를 검토하여 전처리 방 법을 비교 평가하였으며, HPLC-UVD를 이용하여 시료 중 의 자일로올리고당을 분석하였다. 분석 시 1-phenyl-3- methyl-5-pyrazoline (PMP)으로 유도체화하고, photo diode array (PDA)가 장착된 high performance liquid chromatography (HPLC) (Nanospace SI-2)를 사용하였으며, 칼럼은 Cadenza C18 (4.6 × 250 mm, 3 μm)이었으며, 이동상은 pH를 6.0으 로 맞춘 20 mM 인산완충용액과 아세토니트릴을 78:22 비 율로 혼합하여 사용하였고, 0.5 mL/min 유속으로 254 nm 로 하여 분석하였다. 건강기능식품 등 시험법 마련 표준 절차에 관한 가이드라인에 따라 밸리데이션을 수행하고, 표준화된 시험법을 이용하여 유통 중인 건강기능식품 대 상 품목에 대해 시험법 적용 여부를 확인하였다. 표준화 된 시험법은 자일로올리고당을 함유한 건강기능식품 품질 관리에 대한 신뢰성을 더 높일 것으로 본다.

The subacute toxicity of xylooligosaccharide (XO) was evaluated in SD rats. Groups of 60 male and 60 female rats were orally administered with 0, 333, 1000 or 3000 mg/kg of XO for 13 weeks. The changes of body weight, food and water consumption were investigated for 17 weeks, while heamatological values and histopathological findings were investigated at the end of the 13 weeks and 17 weeks including 4 weeks of recovery periods. No death and toxic effects were observed during the test periods. There were statistically significant changes in several parameters, but these change had no direct relationship to dosage. Clinical changes were general occurrence and no specific toxicity was related to XO. Gross necropsy and histopathology revealed that no target organs were found in the treated mouse with XO. According to the results, no-observed effect level of XO is estimated to be above 3000 mg/kg.

To evaluate the bacterial reverse mutation of xylooligosaccharide(XO)s the in vitro Ames test using Salmonella typhimurium (TA98, TA100, TA1535, TA1537) and Escherichia coli (WP2 uvrA) was performed. XO was negative in Ames test with Salmonella typhimurium and Escherichia coli with and without rat liver microsomal enzyme (S-9 fraction). According to the results, XO does not cause bacterial reverse mutation.

The acute toxicity of xylooligosaccharide(XO) was evaluated in SD rats. Groups of 15 male and 15 female rats were orally administered XO (0, 5000 or 10000 ㎎/㎏). The changes of body weight and clinical signs were investigated for 14 days after treatments. No death and toxic effects were observed for 14 days. Soft stool and diarrhea appeared right after treatment for over dose and non-digestive feature of XO but these clinical signs disappeared on the next day. No significant changes in body weight and abnormal gross findings were observed in relation to XO. According to the results, XO has no special toxic effects and LD50 values of XO are above 10000 ㎎/㎏ in male and female rats.